Compare Fox Corp Class A (FOXA) vs Mesoblast Limited (MESO) Price & Performance

FOXA trades at $62.70, up 1.0% with a bearish technical signal despite strong fundamentals. The company reported robust earnings beats in recent quarters with Q2 2026 EPS of $1.79 beating expectations by 24%. Revenue grew to $16.3B in 2025 with net income margin expanding to 13.88%. The pending $22B Roku acquisition faces extended DOJ review, creating regulatory uncertainty while CEO Lachlan Murdoch recently purchased $10.3M in shares.

FOXA presents a compelling value case with attractive valuation multiples (P/E 16.33, P/S 1.61) and strong profitability (ROE 14.29%). Analyst consensus targets $72.00 with 52% buy ratings, offering 15% upside potential. Key risks include regulatory hurdles for the Roku deal and projected 2026 margin compression. The stock's current technical weakness may provide entry opportunity for fundamental investors.

MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.

The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.